2017年8月24日,湖南昭泰醫療集團完全擁有自主知識產權的car-t細胞治療癌癥技術的一期臨床數據成果,已被全球白血病
a novel generation 1928zt2 car t cells induce remission in e
cd215+ myeloid cells respond to interleukin 15 stimulation a
defined, serumfeeder-free conditions for expansion and drug
incorporation of functional elements enhances the antitumor
CRISPR Cas9-Mediated Deletion of Foxn1 in NOD SCID IL2rg KO Mice Results in Severe Immunodeficiency